Medivir AB announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, which was carried out as part of the long-term incentive program […]
Change in the number of shares and votes in Medivir AB (publ) Read More »
En un mundo cada vez más conectado, donde nuestra información personal y financiera se encuentra en línea, la seguridad de nuestras contraseñas se ha convertido en una preocupación primordial. A menudo escuchamos noticias sobre brechas de seguridad y ataques cibern …
Construyendo un muro impenetrable: Cómo crear contraseñas sólidas y seguras Read More »
Asieris Pharmaceuticals announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology annual meeting in Chicago.
Asieris’ progress in MIBC receives renewed attention with its inclusion in ASCO 2023 Read More »
La energía solar fotovoltaica ha experimentado un crecimiento exponencial en las últimas décadas, convirtiéndose en una de las principales fuentes de energía renovable en todo el mundo. Con su capacidad para generar electricidad limpia y abundante a partir de la ra …
Energía Solar Fotovoltaica y Paneles Solares: La revolución energética sostenible Read More »
La Luna, nuestro satélite natural, ha sido un objeto de fascinación y misterio a lo largo de la historia humana. Pero ¿alguna vez te has preguntado qué sucedería si la Luna se liberara de la atracción gravitatoria de la Tierra y fuera arrojada al espacio ext …
El escenario apocalíptico: ¿Qué ocurriría si la Luna escapara de la gravedad terrestre? Read More »
SNIPR Biome ApS announces positive interim clinical results from its Phase 1 clinical trial with SNIPR001, the first CRISPR-armed phage therapeutic developed to specifically target and remove E. coli, including antibiotic-resistant strains, from the human gastrointestinal tract.
Cambrex celebrated the grand opening of its new Q1 Scientific facility in Belgium and announced the signing of a new commercial agreement with QUALIblood, a Belgium-based contract research organization supporting pharmaceutical companies, invitro diagnosis companies, hospitals and universities with analytical services for blood investigations and hemocompatibility testing.
AbbVie announced the results of the Phase 2 SLEek study evaluating upadacitinib alone and in combination [ABBV-599 high dose ] in adults with moderately to severely active systemic lupus erythematosus who continued to receive standard lupus therapies.
THINK Surgical, Inc. recently announced that its TMINI™ Miniature Robotic System has received 510 clearance from the U.S. Food and Drug Administration.
ValnevaSE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon.
Valneva Announces the Availability of Documentation for its Shareholder Meeting Read More »
